Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec;20(4):205-9.
doi: 10.3341/kjo.2006.20.4.205.

Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema

Affiliations

Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema

Young Jae Choi et al. Korean J Ophthalmol. 2006 Dec.

Abstract

Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.

Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.

Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.
Fig. 2
Fig. 2
Central macular thickness in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.
Fig. 3
Fig. 3
Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.
Fig. 4
Fig. 4
Intraocular pressure in the intravitreal and posterior subtenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.

Similar articles

Cited by

References

    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–1806. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94:761–774. - PubMed
    1. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse macular oedema: long-term visual results. Ophthalmology. 1991;98:1594–1602. - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19. Arch Ophthalmol. 1995;113:1144–1155. - PubMed
    1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology. 2002;109:920–927. - PubMed

MeSH terms